Home > Journals > International Angiology > Past Issues > International Angiology 2009 June;28(3) > International Angiology 2009 June;28(3):170-4

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

Reviews   

International Angiology 2009 June;28(3):170-4

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Buflomedil: potential new indications for an old agent

Tsantilas D. 1, Hatzitolios A. I. 2, Tziomalos K. 2, Papadimitriou D. K. 3

1 Department of Internal Medicine, Georgios Gennimatas Hospital, Thessaloniki, Greece 2 First Propedeutic Department of Internal Medicine, School of Medicine, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece 3 Division of Vascular Surgery, Second Department of Surgery Aristotle University of Thessaloniki, Georgios Gennimatas Hospital, Thessaloniki, Greece


PDF


Our understanding of vascular pathophysiology has significantly improved during the past two decades. Patients with type 2 diabetes mellitus have an increased vascular risk and a series of modifiable risk factors play a crucial role in the atherosclerotic process. The microvascular dysfunction in diabetes results in increased vascular permeability and impaired regulation of blood flow and vascular tone. These changes culminate in nephropathy, retinopathy and neuropathy and probably contribute to the increased vascular morbidity and mortality in this population. Moreover, studies in the skin microvasculature suggest that this microvascular dysfunction contributes significantly to the pathogenesis of diabetic foot. Several studies showed a beneficial effect of vasoactive drugs, including buflomedil, in non-diabetic patients. However, it remains to be established whether these drugs could also be beneficial in the diabetic population, especially in the early stages of diabetes.

top of page